NVCRNovoCure Limited

NVCR Stock Price, Valuation & Chart | NovoCure Limited

Compare

$17.380-0.27 (-1.53%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Medical - Instruments & Supplies NVCR intrinsic value NVCR calculated fair value vs price

Overview Financials Dividends Ratios

NVCR Historical price chart

NVCR Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.02B

PE Ratio-13.37

EPS-1.3

Trading Volume769.57K

Today's High/Low17.88/17.29

Dividend Yield0.00

52 Week High/Low21.45/9.82

Shares Outstanding116.45M

NVCR Financial Statement

NVCR Analyst ratings

NVCR Analysis & performance metrics

NVCR Company profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid…

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant…

NVCR Management team

Name

Position

Ashley CordovaCEO

Chief Executive Officer & Director

Frank Leonard

Executive Vice President & President of Novocure Oncology

Michael Puri

Chief Human Resources Officer

Nicolas Leupin M.B.A., M.D., Ph.D.

Chief Medical Officer

Uri Weinberg M.D., Ph.D.

Chief Innovation Officer

Mukund ParavasthuCOO

Chief Operating Officer

Christoph BrackmannCFO

Chief Financial Officer

Barak Ben-Arye

General Counsel

Name

Position

Ashley CordovaCEO

Chief Executive Officer & Director

Frank Leonard

Executive Vice President & President of Novocure Oncology

Michael Puri

Chief Human Resources Officer

Nicolas Leupin M.B.A., M.D., Ph.D.

Chief Medical Officer

Uri Weinberg M.D., Ph.D.

Chief Innovation Officer

Mukund ParavasthuCOO

Chief Operating Officer

Christoph BrackmannCFO

Chief Financial Officer

Barak Ben-Arye

General Counsel

Management Team

Ashley CordovaCEO

Chief Executive Officer & Director

Frank Leonard

Executive Vice President & President of Novocure Oncology

Michael Puri

Chief Human Resources Officer

Nicolas Leupin M.B.A., M.D., Ph.D.

Chief Medical Officer

Uri Weinberg M.D., Ph.D.

Chief Innovation Officer

Mukund ParavasthuCOO

Chief Operating Officer

Christoph BrackmannCFO

Chief Financial Officer

Barak Ben-Arye

General Counsel

Management

Ashley CordovaCEO

Chief Executive Officer & Director

Frank Leonard

Executive Vice President & President of Novocure Oncology

Michael Puri

Chief Human Resources Officer

Nicolas Leupin M.B.A., M.D., Ph.D.

Chief Medical Officer

Uri Weinberg M.D., Ph.D.

Chief Innovation Officer

Mukund ParavasthuCOO

Chief Operating Officer

Christoph BrackmannCFO

Chief Financial Officer

Barak Ben-Arye

General Counsel

Total 8 executives

NVCR Frequently asked questions

What is NovoCure Limited (NVCR) Stock Price?

Current stock price of NovoCure Limited (NVCR) stock is $17.380. The stock price is -1.53% lower in the session. The intraday range can be seen from this page. Volume of NovoCure Limited (NVCR) stock is 769.57K.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the NovoCure Limited (NVCR) stock price going up or down today?

The stock price of NovoCure Limited (NVCR) can change with earnings, company news, and overall market sentiment. NovoCure Limited operates in the Healthcare / Medical - Instruments & Supplies market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the NovoCure Limited stock expensive at its current price?

Whether NovoCure Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for NVCR on this page is -13.37. EPS on this page is -1.30. Compare those figures with peers and growth expectations before deciding if the current NovoCure Limited price is justified.

How has the stock price of NovoCure Limited (NVCR) performed historically?

Historical performance for NovoCure Limited (NVCR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how NVCR reacted to past earnings and market events.

Should I buy NovoCure Limited (NVCR) stock, at this price?

Buying NovoCure Limited (NVCR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.